134 related articles for article (PubMed ID: 35087003)
1. Clinical and laboratory observation on immunoglobulin replacement therapy switching from an intravenous to a subcutaneous route in a Malaysian X-linked agammaglobulinemia patient.
Adli A; Wahab AA; Abdul Latiff AH; Ismail IH; Faizah MZ; Boekhren KB; Noh LM
Med J Malaysia; 2022 Jan; 77(1):95-97. PubMed ID: 35087003
[TBL] [Abstract][Full Text] [Related]
2. Serial Serum Immunoglobulin G (IgG) Trough Levels in Patients with X-linked Agammaglobulinemia on Replacement Therapy with Intravenous Immunoglobulin: Its Correlation with Infections in Indian Children.
Suri D; Bhattad S; Sharma A; Gupta A; Rawat A; Sehgal S; Singh S; Gupta S
J Clin Immunol; 2017 Apr; 37(3):311-318. PubMed ID: 28321612
[TBL] [Abstract][Full Text] [Related]
3. Long-Term Efficacy and Safety of Hizentra® in Patients with Primary Immunodeficiency in Japan, Europe, and the United States: a Review of 7 Phase 3 Trials.
Jolles S; Rojavin MA; Lawo JP; Nelson R; Wasserman RL; Borte M; Tortorici MA; Imai K; Kanegane H
J Clin Immunol; 2018 Nov; 38(8):864-875. PubMed ID: 30415311
[TBL] [Abstract][Full Text] [Related]
4. [X-linked agammaglobulinemia: experience in a Portuguese hospital].
Fernandes A; Guedes M; Vasconcelos J; Neves E; Fernandes S; Marques L
An Pediatr (Barc); 2015 Mar; 82(3):166-71. PubMed ID: 25443324
[TBL] [Abstract][Full Text] [Related]
5. Immunoglobulin dosage and switch from intravenous to subcutaneous immunoglobulin replacement therapy in patients with primary hypogammaglobulinemia: decreasing dosage does not alter serum IgG levels.
Thépot S; Malphettes M; Gardeur A; Galicier L; Asli B; Karlin L; Gérard L; Laumont R; Doize ML; Arnulf B; Fieschi C; Bengoufa D; Oksenhendler E
J Clin Immunol; 2010 Jul; 30(4):602-6. PubMed ID: 20393788
[TBL] [Abstract][Full Text] [Related]
6. Vedolizumab treatment in a patient with X-linked agammaglobulinemia, is it safe and efficient?
Çekiç Ş; Özgür T; Karalı Y; Özkan T; Kılıç SŞ
Turk J Pediatr; 2019; 61(6):937-940. PubMed ID: 32134589
[TBL] [Abstract][Full Text] [Related]
7. [Intravenous immunoglobulin replacement therapy in X-linked agammaglobulinemia].
Kanegane H; Nomura K; Futatani T; Miyawaki T
Nihon Rinsho Meneki Gakkai Kaishi; 2002 Aug; 25(4):337-43. PubMed ID: 16583740
[TBL] [Abstract][Full Text] [Related]
8. Tubulointerstitial nephritis complicating IVIG therapy for X-linked agammaglobulinemia.
Sugimoto K; Nishi H; Miyazawa T; Wada N; Izu A; Enya T; Okada M; Takemura T
BMC Nephrol; 2014 Jul; 15():109. PubMed ID: 25005715
[TBL] [Abstract][Full Text] [Related]
9. Current Spectrum of Infections in Patients with X-Linked Agammaglobulinemia.
Paccoud O; Mahlaoui N; Moshous D; Aguilar C; Neven B; Lanternier F; Suarez F; Picard C; Fischer A; Blanche S; Lecuit M; Hermine O; Lortholary O;
J Clin Immunol; 2021 Aug; 41(6):1266-1271. PubMed ID: 33880703
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and safety of subcutaneous immune globulin (human), 10% caprylate/chromatography purified in patients with primary immunodeficiency disease.
Wasserman RL; Irani AM; Tracy J; Tsoukas C; Stark D; Levy R; Chen J; Sorrells S; Roberts R; Gupta S
Clin Exp Immunol; 2010 Sep; 161(3):518-26. PubMed ID: 20550549
[TBL] [Abstract][Full Text] [Related]
11. X-linked Agammaglobulinemia.
Suri D; Rawat A; Singh S
Indian J Pediatr; 2016 Apr; 83(4):331-7. PubMed ID: 26909497
[TBL] [Abstract][Full Text] [Related]
12. Enteroviruses in X-Linked Agammaglobulinemia: Update on Epidemiology and Therapy.
Bearden D; Collett M; Quan PL; Costa-Carvalho BT; Sullivan KE
J Allergy Clin Immunol Pract; 2016; 4(6):1059-1065. PubMed ID: 26883540
[TBL] [Abstract][Full Text] [Related]
13. Clinical and Genetic Study of X-linked Agammaglobulinemia Patients (The Benefit of Early Diagnosis).
Alizadeh Z; Dashti P; Mazinani M; Nourizadeh M; Shakerian L; Tajik S; Movahedi M; Mamishi S; Pourpak Z; Fazlollahi MR
Iran J Allergy Asthma Immunol; 2020 Jun; 19(3):305-309. PubMed ID: 32615664
[TBL] [Abstract][Full Text] [Related]
14. X-linked agammaglobulinemia - first case with Bruton tyrosine kinase mutation from Pakistan.
Zaidi SK; Qureshi S; Qamar FN
J Pak Med Assoc; 2017 Mar; 67(3):471-473. PubMed ID: 28304004
[TBL] [Abstract][Full Text] [Related]
15. Identical twins with XLA requiring differing amounts of 20% subcutaneous immunoglobulin secondary to protein-losing enteropathy.
Lan J; Eshun J; Lieberman JA
J Allergy Clin Immunol Pract; 2018; 6(3):1073-1074. PubMed ID: 29339123
[No Abstract] [Full Text] [Related]
16. Eczema and X-linked agammaglobulinaemia.
Hunter HL; McKenna KE; Edgar JD
Clin Exp Dermatol; 2008 Mar; 33(2):148-50. PubMed ID: 18076688
[TBL] [Abstract][Full Text] [Related]
17. Immune globulin subcutaneous, human - klhw 20% for primary humoral immunodeficiency: an open-label, Phase III study.
Sleasman JW; Lumry WR; Hussain I; Wedner HJ; Harris JB; Courtney KL; Mondou E; Lin J; Stein MR
Immunotherapy; 2019 Nov; 11(16):1371-1386. PubMed ID: 31621458
[No Abstract] [Full Text] [Related]
18. A child with X-linked agammaglobulinemia and Kawasaki disease: an unusual association.
Sharma D; Guleria S; Suri D; Rawat A; Garg R; Singh S
Rheumatol Int; 2017 Aug; 37(8):1401-1403. PubMed ID: 28365793
[TBL] [Abstract][Full Text] [Related]
19. [X-linked agammaglobulinemia in adults. Clinical evolution].
Giorgetti OB; Paolini MV; Oleastro MM; Fernández Romero DS
Medicina (B Aires); 2016; 76(2):65-70. PubMed ID: 27135842
[TBL] [Abstract][Full Text] [Related]
20. Emerging Paradigm of Primary Immunodeficiency Disease: Individualizing Immunoglobulin Dose and Delivery to Enhance Outcomes.
Shapiro RS; Wasserman RL; Bonagura V; Gupta S
J Clin Immunol; 2017 Feb; 37(2):190-196. PubMed ID: 24477950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
